HDAC3 and cancer: Thus, targeted therapy-induced suppression of DNA repair processes such as HR can lead to a “BRCA-like” state in cancer cells that sensitizes them to poly (ADP-ribose) polymerase (PARP) inhibitors or agents like histone deacetylase 3 (HDAC3) inhibitors that can suppress expression of non-homologous end joining (NHEJ) genes (8, 9, 11, 12).